Solvay extends Quintiles partnership

By staff reporter

- Last updated on GMT

Related tags: Medicine, Quintiles

Solvay Pharmaceuticals said it has decided to renew its clinical
development contract with Quintiles for further five years.

Under the existing partnership the two firms have worked together since 2001, completing three Phase III clinical testing programs, moving two compounds from Phase II to Phase III and produced conclusive Phase II data that resulted in the termination of two other programs. "Using Quintiles' global infrastructure and experts we've advanced projects at a much faster rate than we could have achieved alone, and with greater flexibility,"​ said Werner Cautreels, CEO of Solvay. "Over the next five years we aim to achieve even higher levels of value in terms of efficiency, speed and cost-savings."​ No other terms of the deal were released by the Belgian pharma firm, who specialises developing drugs for areas of unmet medical need in the fields of neuroscience, cardio-metabolic, influenza vaccines and gastroenterology.

Related news

Show more

Related products

show more

A Winning End-to-End Solution for Oncology Studies

A Winning End-to-End Solution for Oncology Studies

Clinical Ink | 22-Feb-2021 | Technical / White Paper

Oncology clinical trials present a unique set of challenges for patients, study sites, and study sponsors. Using electronic patient reported outcomes (ePRO)...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us

Products

View more

Webinars